1,2,3-Triazolyl-4-oxoquinolines: A feasible beginning for promising chemical structures to inhibit oseltamivir-resistant influenza A and B viruses
- Bioorg Med Chem. 2015 Dec 15;23(24):7777-84. doi: 10.1016/j.bmc.2015.11.028.
- 1. Universidade Federal Fluminense, Instituto de Química-Outeiro de São João Batista, s/n°.Campus do Valonguinho, Centro, Niterói, RJ CEP 24020-150, Brazil.
- 2. Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Laboratório de Vírus Respiratórios, NIC-WHO, Rio de Janeiro, RJ CEP 21041-360, Brazil; Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Laboratório de Imunofarmacologia, Rio de Janeiro, RJ CEP 21041-360, Brazil; Fundação Oswaldo Cruz, Centro de Desenvolvimento Tecnológico em Saúde, Rio de Janeiro, RJ CEP 21041-360, Brazil.
- 3. Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Laboratório de Vírus Respiratórios, NIC-WHO, Rio de Janeiro, RJ CEP 21041-360, Brazil.
- 4. Universidade Federal Fluminense, Instituto de Química-Outeiro de São João Batista, s/n°.Campus do Valonguinho, Centro, Niterói, RJ CEP 24020-150, Brazil. Electronic address: [email protected].
We described the synthesis of a new congener series of 1,2,3-triazolyl-4-oxoquinolines and evaluated their ability to inhibit oseltamivir (OST)-resistant influenza strains. Oxoquinoline derivative 1i was the most potent compound within this series, inhibiting 94% of wild-type (WT) influenza neuraminidase (NA) activity. Compound 1i inhibited Influenza Virus replication with an EC50 of 0.2μM with less cytotoxicity than OST, and also inhibited different OST-resistant NAs. These results suggest that 1,2,3-triazolyl-4-oxoquinolines represent promising lead molecules for further anti-influenza drug design.